FDA Pharmacy Compounding Advisory Committee members voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 free base and acetate forms to the 503A bulks list for evaluation in compounding, overriding FDA staff concerns over limited human data, immunogenicity risks, and peptide characterization. This followed the substance’s removal from interim Category 2 status in April 2026 after nomination withdrawals under HHS leadership. The non-binding advisory step initiates formal rulemaking involving notice-and-comment periods that typically span many months, with no final agency determination issued as of late August 2026. BPC-157 remains unapproved for any use and ineligible for lawful 503A compounding until any list addition is finalized.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
31 ago 2026
31 de agosto de 2026
1%
31 de diciembre de 2026
50%
$3,577 Vol.
31 de agosto de 2026
$1,844 Vol.
1%
31 de diciembre de 2026
$1,733 Vol.
50%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.FDA Pharmacy Compounding Advisory Committee members voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 free base and acetate forms to the 503A bulks list for evaluation in compounding, overriding FDA staff concerns over limited human data, immunogenicity risks, and peptide characterization. This followed the substance’s removal from interim Category 2 status in April 2026 after nomination withdrawals under HHS leadership. The non-binding advisory step initiates formal rulemaking involving notice-and-comment periods that typically span many months, with no final agency determination issued as of late August 2026. BPC-157 remains unapproved for any use and ineligible for lawful 503A compounding until any list addition is finalized.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Mercado abierto: Jun 22, 2026, 10:10 PM ET
Volumen
$3,577Fecha de finalización
1 ene 2027Mercado abierto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.FDA Pharmacy Compounding Advisory Committee members voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 free base and acetate forms to the 503A bulks list for evaluation in compounding, overriding FDA staff concerns over limited human data, immunogenicity risks, and peptide characterization. This followed the substance’s removal from interim Category 2 status in April 2026 after nomination withdrawals under HHS leadership. The non-binding advisory step initiates formal rulemaking involving notice-and-comment periods that typically span many months, with no final agency determination issued as of late August 2026. BPC-157 remains unapproved for any use and ineligible for lawful 503A compounding until any list addition is finalized.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volumen
$3,577Fecha de finalización
1 ene 2027Mercado abierto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...FDA Pharmacy Compounding Advisory Committee members voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 free base and acetate forms to the 503A bulks list for evaluation in compounding, overriding FDA staff concerns over limited human data, immunogenicity risks, and peptide characterization. This followed the substance’s removal from interim Category 2 status in April 2026 after nomination withdrawals under HHS leadership. The non-binding advisory step initiates formal rulemaking involving notice-and-comment periods that typically span many months, with no final agency determination issued as of late August 2026. BPC-157 remains unapproved for any use and ineligible for lawful 503A compounding until any list addition is finalized.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes